Innate B cells and natural antibodies (Nabs) have been extensively studied in normal physiological conditions as well as in several diseases. However, their significance in the context of ABO-compatible solid organ transplantation is only emerging. This review summarizes recent studies exploring these often neglected innate immune elements in situations related to sensitization and clinical graft rejection. A focus is placed on class-switched IgG Nabs that develop amidst inflammation, rather than IgM Nabs abundant at the steady state, as new evidence point to their implication in serum reactivity to HLA and kidney graft failure. The involvement of innate B cells in the pathophysiology of CAV is also presented. Lastly, we discuss key questions that need answering to understand whether and how innate B-cell immunity contributes to the outcome of solid organ transplantation.
| INTRODUC TI ON
Humoral immunity to allografts is traditionally divided in two main arms. The adaptive B-cell immunity involves the production of highaffinity antibodies reactive to antigens displayed on donor cells through a process requiring T cell help. These are mostly antibodies specific to donor MHC class I and class II molecules, also called donorspecific antibodies (DSA), considered to be the major pathogenic elements in antibody-mediated rejection. 1, 2 Autoantibodies to selfantigens such as vimentin, cardiac myosin, and angiotensin II type 1 receptor are also presumed to originate from T cell-dependent classswitched follicular B-cell responses. [3] [4] [5] [6] [7] [8] The second arm corresponds to innate B-cell immunity and encompasses preexisting antibodies to ABO blood group antigens as well as xenoantibodies such as IgM reactive to Gal α-1, 3 Gal. 9 Xenoantibodies share a number of characteristics with "natural antibodies" (Nabs) a category of immunoglobulins described in animals and humans in both health and disease. 10 Here,
we will focus on Nabs and summarize recent observations supporting a contribution of these antibodies in the outcome of kidney and heart transplantation. We will also discuss the implication of Nabs in the assessment of serum reactivity in transplant recipients.
Nabs were described more than 50 years ago, 11 yet for the larger community of immunologists, these antibodies are still ill-defined and their function unclear. Perhaps the main hurdle comes from their lack of specificity, which is also their primary characteristic. Most Nabs are polyreactive in that they react to multiple, seemingly unrelated, antigenic structures, including determinants on apoptotic cells, oxidation-specific epitopes, tumor-associated carbohydrates (mucins), components of senescent red blood cells, and various self-proteins. 10 The reactivity of a monoclonal Nab, M2.3, generated from the blood of a healthy donor is shown in Figure 1 as an example. This monoclonal Nab reacts to LPS, insulin, double-stranded DNA, single-stranded DNA as well as permeabilized Hep-2 cells ( Figure 1A ,B). The polyreactivity of M2.3, however, is best illustrated when the monoclonal antibody is used to probe proteins separated from an epithelial cell lysate by electrophoresis on a polyacrylamide gel. As presented in Figure 1C , a great number of proteins are recognized by this single monoclonal Nab, highlighting its broadly crossreactive nature. M2.3 also reacts to late apoptotic cells, a hallmark of serum Nabs ( Figure 1D ). While Nabs are primarily IgM, they can also be detected as IgG in the serum of healthy individuals, albeit at a much lower concentration. In certain pathological conditions, however, the level of IgG Nabs can markedly increase. [12] [13] [14] It is assumed that this increase results from class-switch recombination (CSR) of a preexisting pool of innate B cells toward IgG-secreting plasmablasts or plasma cells as illustrated in Figure 2 . The remainder of this review will focus on IgG Nabs and their implication in the immunology of solid organ transplantation.
| NABS AND S ERUM RE AC TIVIT Y TO HL A
In recent years, Luminex-based assays have become the test of choice to detect anti-HLA antibodies in patient serum. 15 The sensitivity of these assays surpasses that of previous methods. Moreover, the use of beads coated with single HLA molecules allows the precise determination of the serum reactivity to specific antigens. The flip side of such sensitivity is that Luminex tests can also detect non-specific antibodies, resulting in false-positive readings. 16 
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are usually assumed to be cross-reactive to several HLA. In itself, a certain level of cross-reactivity is expected due to the high sequence homology and the presence of immunogenic "public" epitopes shared among HLA. 19, 20 Gao et al 21 proposed an alternate mechanism that may substantially contribute to serum reactivity to HLA observed with Luminex assays. The authors derived Nabs-producing B-cell clones from the peripheral blood and graft infiltrates of kidney transplant recipients. Assessing the reactivity of the monoclonal antibodies secreted by these innate B cells, they observed that a small percentage also reacted to SAB used in Luminex. 21 These monoclonal antibodies display the characteristic polyreactive profile of Nabs, that is, reactivity to LPS, apoptotic cells, dsDNA, and other antigenic structures and also reacted to numerous HLA class I coated on SAB.
Each clone's reactivity pattern was unique and covered up to 45 distinct molecules. 21 Remarkably, the complex reactivity profiles could not be explained by the presence of epitopes shared among the different antigens. Thus far, no polyreactive monoclonal Nab binding to class II molecules was found, suggesting that they may be less frequent than HLA class I-reactive clones. The study also revealed that serum adsorption on apoptotic cells reduced the overall serum reactivity to class I molecules, MICA and, to a lesser extent, HLA class II molecules for some kidney transplant recipients. This report provides supportive evidence that serum Nabs cross-reactive to HLA on SAB are detectable by Luminex and can significantly contribute to the observed anti-HLA reactivity in patient serum samples. For example, the presence of Nabs could explain the detection of NDSA in the absence of prior immunizing events. 22, 23 Based on this observation, Nabs should be taken into account when interpreting complex results from Luminex assays or other methods used to assess serum anti-HLA antibodies.
| NABS , ANTIBODY-MEDIATED RE JEC TI ON , AND K IDNE Y G R AF T LOSS
Until recently, Nabs had only been implicated in graft rejection in the context of xenotransplantation or ABO incompatible transplantation. In both situations, preformed Nabs in the host react vigorously to xeno-or allogeneic carbohydrate determinants on the donor endothelium, triggering a hyperacute form of rejection. In 2013, a cross-sectional case-control study by Porcheray et al, 24 using retrospective samples from two small cohorts, reported higher serum levels of IgG Nabs in kidney transplant recipients with ABMR. In this study, Nabs were detected using flow cytometry by their capacity to bind apoptotic cells. Moreover, these Nabs could activate complement, leading to C4d deposition on target cells in vitro, suggesting a similar function in vivo. This was arguably the first report of Nabs having potentially contributed to ABMR. A subsequent single-center study by the same group showed that higher levels of IgG Nabs pretransplant were associated with reduced graft survival after kidney transplantation in non-sensitized recipients. 25 Even though measurements were carried out using pre-transplant serum, the effect on graft loss was only apparent after 1 year post-transplant, implying a mechanism distinct from that seen in cases of hyperacute rejection. In this latter report, graft loss was also associated with ABMR.
Remarkably, IgG Nabs were almost exclusively of the IgG1 and IgG3 subclasses and could activate complement in vitro, corroborating previous observations. and tubulitis as well as arteriosclerosis. 26 The significance of Nabs in graft loss was further highlighted by the multivariable analysis that isolated DSA and Nabs as two independent immunological risk factors associated with graft loss in this series. The effect of Nabs and DSA was then evaluated separately. Nabs increase alone, that is, in the absence of DSA, was significantly associated with reduced graft survival. However, the highest incidence of graft loss was observed in patients with both DSA and Nabs, suggesting an additive effect.
Remarkably, the development of Nabs in patients without DSA correlated with higher BANFF scores for 4 of 6 histological markers of graft rejection, including C4d deposition on the graft endothelium.
Taken as a whole, the three studies described above strongly support an important, yet unrecognized role of Nabs in the pathophysiology of ABMR. [24] [25] [26] Most specifically, it is likely that Nabs IgG1 and IgG3 activate complement in vivo and contribute to C4d deposition alongside DSA. Based on these findings, it would be particularly interesting to determine the predictive value of these antibodies for ABMR and their possible usefulness in risk stratification. Determining the kinetics of Nabs development following kidney transplantation in relation to DSA would greatly facilitate this task.
| NABS S EN S ITIZ ATI ON FOLLOWING VENTRICUL AR-A SS IS T DE VICE I M PL A NTATI O N
Ventricular-assist devices (VAD) are now routinely used to correct cardiac circulation in patients with advanced heart failure. VAD can serve as bridge to transplantation or destination therapy. However, long-term VAD use increases the risk of multiple complications such as gastrointestinal bleeding, stroke, or pump thrombosis. 27 VAD also triggers the production of anti-HLA antibodies by an unknown mechanism. [28] [29] [30] HLA. Nevertheless, an association between Nabs levels pre-transplant and primary graft dysfunction was found in this cohort, suggesting that Nabs, or the inflammatory reaction associated with their generation, may have predisposed transplant recipients to this life-threatening complication. As Nabs have been involved in atherosclerosis, 32, 33 it is also very plausible that these antibodies play a part in VAD complications. Additional studies are needed to clarify this potential role.
| INNATE-LIKE B CELL S IN C ARD IAC ALLOG R AF T VA SCULOPATHY
Composite immune infiltrates are frequent in rejected kidney and cardiac allografts during rejection. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] A large B-cell component can almost always be detected in these infiltrates, even in the context of acute T cell-mediated rejection. [45] [46] [47] As determined by immunochemistry, B-cell clusters are invariably adjacent to T cells and frequently intertwined with macrophages. In these infiltrates, B cells display either a memory phenotype or a class-switched IgG-secreting plasma cell phenotype. 37, 43 In heart transplant recipients, these infiltrates have been described in the context of cardiac allograft vasculopathy (CAV)
by independent research groups, including ours. 37, 42, 48 Recently, we reported on the reactivity profile of such graft-infiltrating B cells. More than 100 B-cell clones were isolated from 3 freshly explanted cardiac grafts with CAV and immortalized in vitro by EBV transformation. 48 In all 3 cases, between 46% and 67% of B-cell clones derived from the graft tissue secreted monoclonal Nabs characterized by their reactivity to a combination of LPS, DNA, MDA, apoptotic cells, or cardiolipin. Whether this pattern is found in all types of rejection or only specific to chronic, slow progressing forms like CAV remains to be determined.
B cells are also documented in kidney and liver rejection cases. While the environment may arguably vary for different organs, it is plausible that the immunological contexts may still be similar to that of heart transplants during CAV. A significant fraction of graft-infiltrating B cells in these situations may therefore also be polyreactive innate B cells.
| UNANSWERED QUE S TIONS
Collectively, the studies described in the previous sections and recapped in Figure 2 (blue boxes) portray innate B cells and IgG Nabs in an unusual light, as important immune elements in host interaction with solid organ grafts. Notwithstanding, several critical questions, also included in Figure 2 (red boxes), still await answers. These questions are discussed below:
| Mechanisms of generation of IgG Nabs
The origin of serum IgG Nabs is still undefined. A likely scenario is that innate B cells, constitutively secreting IgM Nabs at the steady state, would undergo CSR in response to the inflammatory milieu 
| Nabs reactivity spectrum
As illustrated in Figure 1C 50 Remarkably, this function does not appear to depend on the reactivity of the IgG Nabs as they primarily form a bridge between ficolin-opsonized bacteria and phagocytes. 50, 52 In systemic lupus erythematosus, IgG Nabs produced at higher levels than in normal physiological conditions are associated with neuronal damage. 
| CON CLUS ION
In conclusion, Nabs and innate B cells are an integrative part of B-cell immunity that has long been neglected when studying rejection of ABO-compatible allotransplants. Yet, evidence is accumulating that this component is far more significant than originally thought. How these elements interact with other immune cells and contribute to the alloresponse awaits further investigation.
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